newsfilter
← Latest News
Business Wire·

Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma

– Update based on statistically significant 41% reduction in risk of death vs. previous standard of care in patients with frontline advanced classical Hodgkin lymphoma – – First and only targeted therapy inclusive